---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-289922"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2023-12-06T23:59:59+00:00"
generated_at: "2026-06-07T16:57:15.474095+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Neoleukin faces 3 stockholder suits over Neurogene merger; issues supplemental disclosures

## Summary
- Three lawsuits and ten demands received from stockholders challenging the merger and proxy disclosures.
- Company denies any legal violations but provides supplemental disclosures to avoid litigation disruption.
- Supplemental disclosures amend sections on Transaction Committee composition, valuation DCF, and selected public company analyses.
- DCF implied Neurogene equity value of $445M-$560M; selected companies analysis with 20% illiquidity discount used.
- Executive officers Sean Smith and Donna Cochener entered post-merger consulting negotiations for transition and CVR matters.

## SEC filing metadata
- accession: 0001193125-23-289922
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2023-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000119312523289922/0001193125-23-289922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000119312523289922/d98332d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-289922
- JSON: https://secwatch.observer/filing/0001193125-23-289922.json
- Plain text: https://secwatch.observer/filing/0001193125-23-289922.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.